BSE Live
Mar 20, 16:01Prev. Close
207.30
Open Price
208.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 20, 15:59Prev. Close
207.19
Open Price
210.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Bliss GVS Pharma (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 4.04 | 3.63 | 5.23 | 6.09 | 3.24 | |
| Diluted EPS (Rs.) | 4.04 | 3.63 | 5.23 | 6.09 | 3.24 | |
| Cash EPS (Rs.) | 4.57 | 3.98 | 5.69 | 10.72 | 3.59 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 12.91 | 9.45 | 9.60 | 37.31 | 12.17 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 12.91 | 9.45 | 9.60 | 37.31 | 12.17 | |
| Dividend / Share(Rs.) | 0.50 | 0.15 | 0.10 | 1.00 | 1.00 | |
| Revenue from Operations/Share (Rs.) | 16.37 | 12.89 | 15.88 | 98.85 | 15.45 | |
| PBDIT/Share (Rs.) | 4.97 | 4.47 | 5.95 | 14.97 | 5.41 | |
| PBIT/Share (Rs.) | 4.45 | 4.12 | 5.49 | 10.34 | 5.07 | |
| PBT/Share (Rs.) | 4.44 | 3.90 | 5.28 | 9.29 | 4.99 | |
| Net Profit/Share (Rs.) | 4.04 | 3.63 | 5.23 | 6.09 | 3.24 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 30.38 | 34.67 | 37.44 | 15.14 | 35.02 | |
| PBIT Margin (%) | 27.18 | 31.97 | 34.58 | 10.46 | 32.81 | |
| PBT Margin (%) | 27.09 | 30.27 | 33.23 | 9.39 | 32.28 | |
| Net Profit Margin (%) | 24.70 | 28.16 | 32.94 | 6.16 | 20.99 | |
| Return on Networth / Equity (%) | 31.32 | 38.40 | 54.51 | 16.32 | 26.67 | |
| Return on Capital Employed (%) | 30.50 | 37.84 | 52.87 | 14.91 | 23.36 | |
| Return on Assets (%) | 26.14 | 29.47 | 31.38 | 6.65 | 14.62 | |
| Total Debt/Equity (X) | 0.06 | 0.02 | 0.20 | 0.32 | 0.11 | |
| Asset Turnover Ratio (%) | 105.84 | 104.64 | 95.25 | 108.07 | 69.62 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 5.93 | 3.64 | 2.12 | 1.31 | 1.84 | |
| Quick Ratio (X) | 4.58 | 2.27 | 1.68 | 1.21 | 1.64 | |
| Inventory Turnover Ratio (X) | 5.51 | 3.44 | 5.35 | 18.31 | 9.26 | |
| Dividend Payout Ratio (NP) (%) | 14.46 | 4.13 | 1.91 | 16.41 | 30.81 | |
| Dividend Payout Ratio (CP) (%) | 12.80 | 3.76 | 1.76 | 9.33 | 27.88 | |
| Earnings Retention Ratio (%) | 85.54 | 95.87 | 98.09 | 83.59 | 69.19 | |
| Cash Earnings Retention Ratio (%) | 87.20 | 96.24 | 98.24 | 90.67 | 72.12 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 362.62 | 97.48 | 289.56 | 35.67 | 15.00 | |
| EV/Net Operating Revenue (X) | 2.15 | 0.73 | 2.83 | 0.57 | 2.67 | |
| EV/EBITDA (X) | 7.07 | 2.11 | 7.55 | 3.78 | 7.61 | |
| MarketCap/Net Operating Revenue (X) | 2.19 | 0.77 | 2.77 | 0.52 | 2.66 | |
| Retention Ratios (%) | 85.53 | 95.86 | 98.08 | 83.58 | 69.18 | |
| Price/BV (X) | 2.78 | 1.05 | 4.58 | 1.37 | 3.37 | |
| Price/Net Operating Revenue | 2.19 | 0.77 | 2.77 | 0.52 | 2.66 | |
| Earnings Yield | 0.11 | 0.37 | 0.12 | 0.12 | 0.08 |
20.02.2026
Bliss GVS Consolidated December 2025 Net Sales at Rs 218.25 crore, up 3.72% Y-o-Y
19.02.2026
Bliss GVS Standalone December 2025 Net Sales at Rs 164.68 crore, down 8.3% Y-o-Y
07.11.2025
Bliss GVS Consolidated September 2025 Net Sales at Rs 244.40 crore, up 12.27% Y-o-Y
30.07.2025
Bliss GVS Consolidated June 2025 Net Sales at Rs 207.47 crore, up 12.97% Y-o-Y
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
20.03.2026
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
20.03.2026
20.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth